Join our podcast as we unpack a study exploring the potential of the asthma medication formoterol as a novel treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe liver condition often linked to diabetes.
The researchers used experiments involving high-fat diet mice and human liver cell cultures to show that this beta 2 adrenergic receptor agonist effectively reduces liver fat accumulation. It does so by stimulating mitochondrial biogenesis and enhancing metabolic efficiency. In addition, a massive retrospective analysis of nearly 60 000 patients revealed that those using long-acting versions of these drugs experienced significantly lower rates of liver complications and reduced mortality.
